These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 36910721)

  • 81. In Vivo Anticancer Efficacy and Toxicity Studies of a Novel Polymer Conjugate N-Acetyl Glucosamine (NAG)-PEG-Doxorubicin for Targeted Cancer Therapy.
    Pawar S; Mahajan K; Vavia P
    AAPS PharmSciTech; 2017 Nov; 18(8):3021-3033. PubMed ID: 28497240
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Disaccharide-modified liposomes and their in vitro intracellular uptake.
    Song CK; Jung SH; Kim DD; Jeong KS; Shin BC; Seong H
    Int J Pharm; 2009 Oct; 380(1-2):161-9. PubMed ID: 19635539
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Targeting the cytotoxicity of fusogenic membrane glycoproteins in gliomas through protease-substrate interaction.
    Johnson KJ; Peng KW; Allen C; Russell SJ; Galanis E
    Gene Ther; 2003 May; 10(9):725-32. PubMed ID: 12704411
    [TBL] [Abstract][Full Text] [Related]  

  • 84. PEG-coated nanoparticles detachable in acidic microenvironments for the tumor-directed delivery of chemo- and gene therapies for head and neck cancer.
    Lo YL; Chang CH; Wang CS; Yang MH; Lin AM; Hong CJ; Tseng WH
    Theranostics; 2020; 10(15):6695-6714. PubMed ID: 32550898
    [No Abstract]   [Full Text] [Related]  

  • 85. Development of paclitaxel loaded pegylated gelatin targeted nanoparticles for improved treatment efficacy in non-small cell lung cancer (NSCLC): an in vitro and in vivo evaluation study.
    Gu M; Luan J; Song K; Qiu C; Zhang X; Zhang M
    Acta Biochim Pol; 2021 Aug; 68(4):583-591. PubMed ID: 34355554
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Tumor-type-dependent vascular permeability constitutes a potential impediment to the therapeutic efficacy of liposomal oxaliplatin.
    Abu Lila AS; Matsumoto H; Doi Y; Nakamura H; Ishida T; Kiwada H
    Eur J Pharm Biopharm; 2012 Aug; 81(3):524-31. PubMed ID: 22554766
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Novel PEG-matrix metalloproteinase-2 cleavable peptide-lipid containing galactosylated liposomes for hepatocellular carcinoma-selective targeting.
    Terada T; Iwai M; Kawakami S; Yamashita F; Hashida M
    J Control Release; 2006 Apr; 111(3):333-42. PubMed ID: 16488046
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies.
    Gabizon A; Shmeeda H; Barenholz Y
    Clin Pharmacokinet; 2003; 42(5):419-36. PubMed ID: 12739982
    [TBL] [Abstract][Full Text] [Related]  

  • 89. A Novel Long-circulating DOX Liposome: Formulation and Pharmacokinetics Studies.
    Xiao P; Zhao J; Huang Y; Jin R; Tang Z; Wang P; Song X; Zhu H; Yang Z; Yu N
    Pharm Nanotechnol; 2020; 8(5):391-398. PubMed ID: 32787769
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Antitumor Effect of Hyperoside Loaded in Charge Reversed and Mitochondria-Targeted Liposomes.
    Feng Y; Qin G; Chang S; Jing Z; Zhang Y; Wang Y
    Int J Nanomedicine; 2021; 16():3073-3089. PubMed ID: 33953556
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Lactoferrin-modified PEGylated liposomes loaded with doxorubicin for targeting delivery to hepatocellular carcinoma.
    Wei M; Guo X; Tu L; Zou Q; Li Q; Tang C; Chen B; Xu Y; Wu C
    Int J Nanomedicine; 2015; 10():5123-37. PubMed ID: 26316745
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Cell-penetrating Peptide-coated Liposomes for Drug Delivery Across the Blood-Brain Barrier.
    Yuan BO; Zhao Y; Dong S; Sun Y; Hao F; Xie J; Teng L; Lee RJ; Fu Y; Bi YE
    Anticancer Res; 2019 Jan; 39(1):237-243. PubMed ID: 30591464
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Comparative effects of free doxorubicin, liposome encapsulated doxorubicin and liposome co-encapsulated alendronate and doxorubicin (PLAD) on the tumor immunologic milieu in a mouse fibrosarcoma model.
    Islam MR; Patel J; Back PI; Shmeeda H; Adamsky K; Yang H; Alvarez C; Gabizon AA; La-Beck NM
    Nanotheranostics; 2022; 6(4):451-464. PubMed ID: 36105861
    [No Abstract]   [Full Text] [Related]  

  • 94. High Tumor Penetration of Paclitaxel Loaded pH Sensitive Cleavable Liposomes by Depletion of Tumor Collagen I in Breast Cancer.
    Zhang L; Wang Y; Yang Y; Liu Y; Ruan S; Zhang Q; Tai X; Chen J; Xia T; Qiu Y; Gao H; He Q
    ACS Appl Mater Interfaces; 2015 May; 7(18):9691-701. PubMed ID: 25845545
    [TBL] [Abstract][Full Text] [Related]  

  • 95. The effect of RGD-targeted and non-targeted liposomal Galbanic acid on the therapeutic efficacy of pegylated liposomal doxorubicin: From liposomal preparation to in-vivo studies.
    Nik ME; Jaafari MR; Mashreghi M; Nikoofal-Sahlabadi S; Amin M; Sadeghnia HR; Iranshahi M; Navashenaq JG; Malaekeh-Nikouei B
    Int J Pharm; 2021 Jul; 604():120710. PubMed ID: 34019972
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Tat peptide and hexadecylphosphocholine introduction into pegylated liposomal doxorubicin: An in vitro and in vivo study on drug cellular delivery, release, biodistribution and antitumor activity.
    Teymouri M; Badiee A; Golmohammadzadeh S; Sadri K; Akhtari J; Mellat M; Nikpoor AR; Jaafari MR
    Int J Pharm; 2016 Sep; 511(1):236-244. PubMed ID: 27363937
    [TBL] [Abstract][Full Text] [Related]  

  • 97. MT1-MMP-Activated Liposomes to Improve Tumor Blood Perfusion and Drug Delivery for Enhanced Pancreatic Cancer Therapy.
    Wei Y; Song S; Duan N; Wang F; Wang Y; Yang Y; Peng C; Li J; Nie D; Zhang X; Guo S; Zhu C; Yu M; Gan Y
    Adv Sci (Weinh); 2020 Sep; 7(17):1902746. PubMed ID: 32995113
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Matrix Metalloproteinase-Responsive Delivery of PEGylated Fibroblast Growth Factor 2.
    Gutmann M; Reinhardt D; Seidensticker C; Raschig M; Hahn L; Moscaroli A; Behe M; Meinel L; Lühmann T
    ACS Biomater Sci Eng; 2024 Jan; 10(1):156-165. PubMed ID: 37988287
    [TBL] [Abstract][Full Text] [Related]  

  • 99. PEG-liposomal doxorubicin as a potential agent for canine metastatic osteosarcoma -
    Walewska M; Małek A; Taciak B; Wojtalewicz A; Wilk S; Wojtkowska A; Zabielska-Koczywąs K; Lechowski R
    J Vet Res; 2023 Jun; 67(2):297-305. PubMed ID: 37786430
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Liposomal delivery of organoselenium-cisplatin complex as a novel therapeutic approach for colon cancer therapy.
    Khabbazian S; Mirhadi E; Gheybi F; Askarizadeh A; Jaafari MR; Alavizadeh SH
    Colloids Surf B Biointerfaces; 2024 Oct; 242():114085. PubMed ID: 39018910
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.